Your session is about to expire
← Back to Search
AlphaMedix for Neuroendocrine Cancer (ALPHAMEDIX02 Trial)
ALPHAMEDIX02 Trial Summary
This trial is testing a new cancer treatment for people with neuroendocrine tumors.
ALPHAMEDIX02 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowALPHAMEDIX02 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From undefined Phase 2 trial • 4 Patients • NCT00005906ALPHAMEDIX02 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition worsened after treatment with somatostatin analogs.My cancer has worsened within the last year and can be measured.I have a history of myelodysplastic syndrome.My recent blood tests show my organs and bone marrow are working well.I have had whole-body radiotherapy or specific targeted radiation therapy.My cancer shows high activity on specific scans compared to normal liver.All my cancer lesions have somatostatin receptors, confirmed by a recent PET/CT scan.I am not pregnant or breastfeeding.My cancer has worsened within the last year and can be measured.My cancer shows high activity on specific scans compared to normal liver.I haven't had liver-targeted radiation in the last 4 months or non-radiation liver therapy in the last 6 months.All my cancer lesions have somatostatin receptors, confirmed by a specific PET/CT scan within the last 6 weeks.My brain metastases have been stable or treated for at least 6 months.I am able to get out of my bed or chair and move around.My diabetes is not under control, with an A1C level over 10.0.I haven't used any somatostatin drugs like Sandostatin in the last 28 days.My doctor believes surgery could potentially cure my condition.I have no other cancers except for non-dangerous skin cancer or treated cervical cancer with no signs of return in 5 years.My cancer has visible signs on scans that meet specific criteria.I am 18 or older with a NET that cannot be surgically removed or has spread.I have bone cancer that can be measured by scans.My tests show a blockage in my kidneys.My condition worsened after receiving somatostatin analog treatment.My heart condition is not under control.I do not have active HIV or hepatitis B/C, or if I had, it is now cured.I haven't taken any experimental cancer treatments in the last 6 weeks.I can take care of myself and am up and about more than half of the day.
- Group 1: Pb212-DOTAMTATE
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What precedent has AlphaMedix established in terms of conducting medical tests?
"Currently, there are 16 clinical studies pertaining to AlphaMedix with 5 trials in Phase 3. Whilst the majority of these investigations take place in Trabzon and Florida, a total of 792 centres globally offer research into this medication."
Are there any vacancies for prospective participants in this investigation?
"Affirmative, the clinical trial is open for recruitment as per records on clinicaltrials.gov. The medical study was initiated on December 21st 2021 and most recently updated on January 5th 2022; it seeks to enroll 34 participants from a single site."
How many participants have signed up for this trial thus far?
"Affirmative. According to the information hosted on clinicaltrials.gov, this medical research is currently in search of 34 patients from a single centre. The project was initially posted on December 21st 2021 and most recently edited on January 5th 2022."
What indications is AlphaMedix regularly utilized to address?
"AlphaMedix has been found to be effective in managing the symptoms of acromegaly, octreotide use and long-term maintenance therapy."
What potential hazards can be associated with AlphaMedix consumption?
"AlphaMedix has been attributed a safety score of 2, as the current Phase 2 trial only provides limited evidence on its efficacy and some data supporting safety."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Excel Diagnostics and Nuclear Oncology Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger